Czech clinical research center specializing in cardiac ablation therapies and transplant immunosuppression, contributing patient cohorts to large European trials.
IKEM (Institute for Clinical and Experimental Medicine) is one of the Czech Republic's leading clinical research centers, specializing in organ transplantation, cardiovascular medicine, and advanced interventional therapies. Their H2020 work focuses on clinical validation of emerging treatment technologies — from electroporation-based cardiac ablation to personalized immunosuppression after kidney transplants. They contribute clinical expertise and patient cohorts to large European multicenter trials, bridging the gap between experimental therapies and routine clinical practice.
BEAT AF explores electroporation-based pulmonary vein isolation, while STOPSTORM validates stereotactic radiotherapy for ventricular tachycardia — both advancing alternatives to conventional radiofrequency ablation.
TTV GUIDE TX is a Phase II clinical trial personalizing immunosuppressive therapy by monitoring Torque Teno Virus load post-transplant, directly building on IKEM's established transplant program.
STOPSTORM investigates non-invasive stereotactic ablative radiotherapy (SABR/SBRT) for re-entrant ventricular tachycardia — a frontier approach crossing cardiology and radiation oncology.
TTV GUIDE TX uses viral load (TTV) as a surrogate biomarker for immune status, contributing to the broader field of precision medicine in transplantation.
All three H2020 projects started in 2021, so a clear temporal shift within Horizon 2020 cannot be established. However, the portfolio reveals a consistent institutional strategy: IKEM participates in clinical validation trials that test next-generation interventions against established standards of care. Their work spans two of their longstanding strengths — cardiac electrophysiology and transplant medicine — suggesting a mature research center deploying existing clinical infrastructure into European collaborative trials rather than pivoting to new domains.
IKEM is moving toward precision and personalization in both cardiology and transplant medicine, making them a strong partner for trials that need experienced clinical sites with large patient populations.
IKEM operates exclusively as a participant, never coordinating — consistent with a clinical center that provides patient access, clinical expertise, and trial site infrastructure rather than managing consortium logistics. With 55 unique partners across just 3 projects, they work in large multicenter consortia (averaging ~18 partners per project), which is typical for clinical validation studies requiring diverse patient cohorts across Europe. This makes them a reliable, low-overhead partner: they deliver clinical data without demanding project leadership.
IKEM has collaborated with 55 unique partners across 12 countries through large clinical trial consortia. Their network spans Western and Central Europe, reflecting the geographic spread typical of multicenter clinical validation studies.
IKEM is one of Central Europe's largest transplant and cardiovascular centers, giving it access to patient populations that are essential for powering clinical trials. Unlike university hospital groups that cover many specialties thinly, IKEM concentrates on cardiology and organ transplantation with deep institutional expertise. For consortium builders, they offer a proven clinical trial site in the Czech Republic — a country with competitive clinical costs and strong regulatory infrastructure for medical research.
